Patent intelligence · US
US 8962797
Halogenated compounds for photodynamic therapy
Halogenated compounds for photodynamic therapy
Patent details — US 8962797
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 24, 2015
- Expiration
- Feb 19, 2035
- Applicant
- NANOQUANTUM SCIENCES, INC.
- Claims
- 22
- CPC classes
- A61K, A61K31/403, A61K31/404, A61K31/438
Quick answer
US 8962797 (Halogenated compounds for photodynamic therapy) is held by NANOQUANTUM SCIENCES, INC.. Status: granted. Granted Feb 24, 2015. Expires Feb 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- NANOQUANTUM SCIENCES, INC.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K31/403, A61K31/404, A61K31/438, A61K41/0057, A61K41/0071
More from NANOQUANTUM SCIENCES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12391720
Salts and polymorphs of cethromycin for the treatment of disease
granted -
US 12377151
Immobilized endoglycosidase fusion protein and use thereof
granted -
US 12370266
Polymer composite nanomaterial encapsulation system
granted -
US 12318457
Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof
granted -
US 12312377
Biconjugatable labels and methods of use
granted -
US 12195454
Compounds for imaging tau proteins that accumulate in the brain
granted -
US 12102694
Radiolabeled compound producing method and producing apparatus, radiolabeled compound and radioisotope producing apparatus
granted -
US 11999748
Exatecan derivatives, linker-payloads, and conjugates and thereof
granted
Frequently asked questions
What is US patent 8962797?
US 8962797 (Halogenated compounds for photodynamic therapy) is held by NANOQUANTUM SCIENCES, INC.. Status: granted. Granted Feb 24, 2015. Expires Feb 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8962797?
NANOQUANTUM SCIENCES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 8962797 expire?
Our index shows an expiration date of Feb 19, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.